Role of apoptosis in autoimmune thyroid disorders;Rola apoptozy w chorobach autoimmunologicznych tarczycy

Endokrynologia, Diabetologia i Choroby Przemiany Materii Wieku Rozwojowego

Volumn 12, Issue 3, 2006, Pages 216-220

  Bossowski, Artur ^a   Moniuszko, Anna ^b   Bouzyk, Joanna ^b   Urban, Mirosława ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b NONE   (Poland)

Author keywords

Apoptosis; Autoimmune thyroid disorders; bcl 2; Cytokines; FasL; TNF; TRAIL

Indexed keywords

CYTOKINE; FAS LIGAND; PROTEIN BCL 2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; AUTOIMMUNE DISEASE; CELL DEATH; CELL METABOLISM; GENE ACTIVATION; GRAVES DISEASE; HASHIMOTO DISEASE; PATHOGENESIS; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; THYROID DISEASE;

ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNE DISEASES; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; THYROID DISEASES; THYROIDITIS, AUTOIMMUNE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTORS;

EID: 33749481903     PISSN: 1234625X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Sakagauchi S.: Animal models of autoimmunity and their relevance to human diseases. Curt. Opin. Immunol., 2000, 12, 684-609.
2. Kawakami A., Eguchi K.: Involvement of apoptotic cell death in autoimmune diseases. Med. Electron Microsc. 2002, 35, 1-8
3. Hengartner M.O.: The biochemistry of apoptosis. Nature, 2000, 407, 770-776.
4. Salvesen G.S., Dixit V.M., Caspases: intracellular signaling by proteolysis. Cell, 1997, 91, 443-446.
5. Kroemer G., Zamzami N., Susin S.A.: Mitochondria control of apoptosis. Immunol. Today, 1997, 18, 44-51.
6. Klas C., Debatin K.M., Joker R.R. i wsp.: Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol., 1993, 5, 625-630.
7. Bertin J., Armstrong R.C., Ottilie S. i wsp.: Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas-and TNFR1-induced apoptosis. Proc. Natl. Acad. Sci. USA, 1997, 94, 1172-1176.
8. Green D.R., Reed J.C.: Mitochondria and apoptosis. Science, 1998, 281, 1309-1312.
9. Adams J.M., Cory S.: Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci., 2001, 26, 61-66.
10. Gross A., Yin X.M., Wang K. i wsp.: Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem., 1999, 274, 1156-1163.
11. Hu Y., Benedict M.A., Wu D. i wsp.: Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc. Natl. Acad. Sci. USA, 1998, 95, 4386-4391.
12. Pan G., O'Rourke K., Dixit V.M.: Caspase-9, Bcl-XL and Apaf-1 form a ternary complex. J. Biol. Chem., 1998, 273, 5841-5845.
13. Reed J.C.: Double identity for protein of the Bcl-2 family. Nature, 1997, 387, 773-776.
14. Anzai N., Kawabata H., Hishita T. i wsp.: Distribution of endogenous endonuclease activities capable of producing internucleosomal DNA cleavage in hematopoetic cells. Int. J. Hematol., 1997, 66, 387-390.
15. Enari M., Sakahira H., Yokoyama H. i wsp.: A caspase-activated DNase that degrades DNA during apoptosis and its inhibitor ICAD. Nature, 1998, 391, 43-50.
16. Weetman A.P., McGregor A.M.: Autoimmune thyroid disease, Further developments in our understanding. Endocr. Rev., 1994, 15, 788-830.
17. Del Prete G.F., Vercelli D., Tiri A. i wsp.: In vivo activated cytotoxic T cells in the thyroid infiltrate of patients with Hashimoto's thyroiditis. Clin. Exp. Immunol., 1986, 65, 140-147.
18. Constagliola S., Many M.C., Denef J.F. i wsp.: Genetic immunization of out bred mice with thyrotropin receptor cDNA provides a model of Graves' disease. J. Clin. Incest., 2000, 105, 803-811.
19. Pujol-Borrel R., Todd I., Londei M. i wsp.: New ideas in thyroid autoimmunity. Horm. Res., 1987, 26, 118-124.
20. Baker J.R. Jr: The nature of apoptosis in the thyroid and the role it may play in autoimmune thyroid disease. Thyroid, 2001, 11, 245-247.
21. Stassi G., Zeuner A., Di Liberto D. i wsp.: Fas/FasL in Hashimoto's thyroiditis. J. Clin. Immunol., 2001, 21, 19-23.
22. Leithauser F., Dhein J., Mechtersheimer G. i wsp.: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest., 1993, 69, 415-429.
23. Giordano C., Stassi G., De Maria R. i wsp.: Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science, 1997, 275, 960-963.
24. Bossowski A., Stasiak-Barmuta A., Czarnocka B. i wsp.: Cytofluorymetryczna analiza wybranych markerów apoptozy Fas/FasL (CD95/CD95L) w tkance gruczołu tarczowego u młodocianych pacjentów z choroba̧ Gravesa-Basedowa oraz zapaleniem tarczycy typu Hashimoto. Endokrynol. Diabetol. Chor. Przemiany Materii Wieku Rozw., 2006, 12, 83-90.
25. Stassi G., Todaro M., Bucchieri F. i wsp.: Fas/Fas ligand-driven T cell apoptosis as a conseqence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis. J. Immunol., 1999, 162, 263-267.
26. Friday R.P., Pietropaolo S.L., Profozich J. i wsp.: Alternative core promoters regulate tissue-specific transcription from the autoimmune diabetes-related ICA1 (ICA69) gene locus. J. Biol. Chem., 2003, 278, 853-863.
27. Heter M., Aust G., Ode-Hakim S. i wsp.: Different cytokines mRNA profiles in Graves' disease, Hashimoto's thyroiditis and nonautoimmune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RTPCR). Thyroid, 1996, 6, 97-106.
28. Stassi G., De Maria R.: Autoimmune thyroid disease, new models of cell death in autoimmunity. Nat. Rev. immunol., 2002, 2, 195-204.
29. De Maria R., Testi R.: Fas-FasL interactions, a common pathogenetic mechanizm in organ-specific autoimmunity. Immunol. Today, 1998, 19, 121-125.
30. Wei Y., Chen K., Sharp G.C. i wsp.: Expression and regulation of Fas and Fas ligand on thyrocytes and infiltrating cells during induction and resolution of granulomatosus experimental autoimmune thyroiditis. J. Immunol., 2001, 167, 6678.
31. Fisher G.N., Rosenberg F.J., Strans S.F. i wsp.: Dominant interfering Fas gene mutations impair apoptosis in a human lymphoproliterative syndrome. Cell, 1995, 81, 935-946.
32. Rieux-Loucat R., Le Deist F., Hivroz C. i wsp.: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science, 1995, 268, 1347-1349.
33. Dianzani U., Bragardo M., DiFranco D. i wsp.: Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood, 1997, 89, 2871-2879.
34. Lorenz H.M., Hermann M., Winkler T. i wsp.: Role of apoptosis in autoimmunity. Apoptosis, 2000, 5, 443-449.
35. Ravirajan C.T., Pittoni V., Isemberg D.A.: Apoptosis in human autoimmune diseases. Int. Rev. Immunol., 1999, 18, 563-589.
36. Kawakami A., Eguchi K.: Involvement of apoptotic cell heath in autoimmune diseases. Med. Electron. Microsc., 2002, 35, 1-8.
37. Bretz JD., Baker JR Jr.: Apoptosis and autoimmune thyroid disease, following a TRAIL to thyroid destruction? Clin. Endocrinol., 2001, 55, 1-11.
38. Bretz J.D., Rymaszewski M., Arscott P.L. i wsp.: TRAIL death pathway expression and induction in thyroid follicular cells. J. Biol. Chem., 1999, 274, 23627-23632.
39. Wendung U., Walczak H., Dorr J. i wsp.: Expression of TRAIL receptors in human autoreactive and foreign antygen-specific T cells. Cell Heath and Differentiation, 2000, 7, 637-644.
40. Kroemer G.: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med., 1997, 3, 614-620.
41. Basile D.P., Lapis H., Hammermann M.R.: Expression of Bcl-2 and Bax in regenerating rat renal tubules following inschemic injury. Am. J. Physiol., 1997, 272, 640-647.
42. Mikhailov V., Mikhailova M., Pulkrabek D.J. i wsp.: Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane. J. Biol. Chem., 2001, 276, 18361-18374.
43. Adams J., Cory S.: The Bcl-2 protein family, arbiters of cell survival. Science, 1998, 281, 1322-1326.
44. Zha H., Reed j.C.: Heterodimerization-independent functions of cell Heath regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J. Biol. Chem., 1997, 272, 31482-31488.
45. Ke N., Godzik A., Reed J.C.: Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak. J. Biol. Chem., 2001, 276, 12481-12484.
46. Wei M.C., Zong W.-X., Cheng E.H.-Y. i wsp.: Proapoptotic bax and bak, a requisite gateway to mitochondrial dysfunction and death. Science, 2001, 292, 727-730.
47. Krajewski S., Krajewska M., Reed J.C.: Immunohistochemical analysis of in vivo patterns of Bak expression, a prc-apoptotic member of the Bcl-2 protein family. Cancer Res., 1996, 56, 2849-2855.
48. Palazzo F.F., Hammond L.J., Goode A.W., Mirakian R.: Death of the autoimmune thyrocyte, is it pushed or does it jump? Thyroid, 2000, 10, 561-572.
49. Hammond L.J., Lowdell M.W., Cerrano P.G. i wsp.: Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. J. Pathol., 1997, 182, 138-144.
50. Chen S., Fazle Akbar S.: Analysis of expression of Fas, FasL and Bcl-2 in the pathogenesis of autoimmune thyroid disorders. Cell Mol. Immunol., 2004, 1, 224-228.
51. Strasser A., Harris A.W., Huang D.C. i wsp.: Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J., 1995, 14, 6136-6147.
52. Strasser A., O'Connor L., Dixie V.M.: Apoptosis signaling. Ann. Rev. Biochem., 2000, 69, 217-245.
53. Hiromatsu Y., Kaku H., Mukai T.: Immunohistochemical analysis of Bcl-2, Bax and Bak expression in thyroid glands from patients with Graves' disease. Endocr. J., 2004, 51, 399-405.
54. Riou C., Tonoli H., Bernier-Valentin F. i wsp.: Susceptibility of differentiated thyrocytes in primary culture to undergo apoptosis after exposure to hydrogen peroxide, relation with the level of expression of apoptosis regulatory proteins, Bcl-2 and Bax. Endocrinology, 1999, 140, 1990-1997.
55. Oltvai Z., Milliman C.L., Korsmeyer S.J.: 1993 Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 1993, 74, 609-619
56. Tomer Y., Barbesino G., Greenberg D.A. i wsp.: Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases, evidence for genetic heterogeneity and gene interactions. J. Clin. Endocrinol. Metab., 1999, 84, 4656-4664.
57. Arscott P.L., Knapp J., Rymaszewski M. i wsp.: Fas (APO-1, CD-95) - mediated apoptois in thyroid cells is regulated by labile protein inhibitor. Endocrinology, 1999, 138, 5019-5027.